U.S. stock market midday update: Basel Medical surged 9.67%, with trading volume skyrocketing, attracting market attention

U.S. Stock Market Midday Update Basel Medical, up 9.67%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Cigna Insurance down 1.62%. Based on recent key news: On January 7, an investigation by Hunterbrook Media revealed that Cigna Insurance, along with two other U.S. healthcare giants, used shell companies to conceal funds, potentially affecting drug costs. This news triggered a crisis of confidence in Cigna Insurance, leading to a drop in stock price. On January 5, Cigna Insurance's target price was raised from $310 to $320, showing market confidence in its long-term growth. However, the impact of recent negative news overshadowed this positive development. On January 6, the market expressed concern over Cigna Insurance's asset management and operational excellence, but this did not offset the negative impact of the investigation. The healthcare industry is facing regulatory pressure, with significant capital outflows. Hims & Hers Health up 0.17%. Based on recent news, On January 6, Hims & Hers Health performed best in a month and continued to rise after hours. Novo expanded the use of oral Wegovy, while Citibank maintained a "sell" rating on Hims. Hims continues to expand its platform through international growth and new services. On January 6, brokerage TD Cowen lowered Hims & Hers' target price from $48 to $37 due to valuation issues. Nevertheless, the brokerage remains optimistic about its strong growth prospects, believing that Hims' focus on personalized care drives subscription user growth. On January 5, Hims & Hers' adjusted EBITDA showed the company's risks in expanding across multiple areas. However, analysts believe the current stock price is reasonable and recommend buying on price dips. The increasing demand for personalized care platforms is driving Hims & Hers' growth. CVS Health down 0.70%. Based on recent news, On January 7, an investigation by Hunterbrook Media revealed that CVS Health, UnitedHealth, and Cigna Group used shell companies to hide funds, potentially affecting drug costs. CVS did not issue a statement on this, leading to market doubts about its transparency, putting pressure on the stock price. On January 6, CVS Health announced a quarterly dividend of $0.665 per share, with a payment date of February 2, 2026. Although this news is generally seen as positive, it failed to significantly boost the stock price On January 5th, CVS Health plans to partially commercialize its engagement platform, providing digital engagement capabilities to employers, payers, and other partners. Although this plan demonstrates the company's intention to expand its business, the market reaction has been tepid. The healthcare industry has been quite volatile recently, and attention should be paid to policy changes. Stocks Ranked Among the Top by Market Capitalization in the Industry Experimental Biotech fell 2.40%, with a market capitalization of $21.1 billion and increased trading volume, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation